GSK
Precision Cancer Consortium Launches With Bayer, GSK, Roche, Novartis as Founding Members
The organization of pharmaceutical and biotechnology firms aims to increase access to genomic testing for cancer patients.
LifeMine Therapeutics Nets $175M in Series C, Inks GSK Deal to Advance Genomically Informed Drugs
The firm will use the funds to advance its Avatar-Rx platform and identify small molecules in nature that can be directed at difficult-to-treat cancer targets.
Lyell Immunopharma's IND for T-Cell Receptor Therapy Gets FDA Clearance
The company will begin a Phase I trial of LYL132 in certain patients with NY-ESO-1-expressing advanced sarcomas.
During its R&D day, 23andMe outlined the genetics rationale for two cancer drugs it is developing and said it will apply genotyping across trials to identify best responders.
23andMe Gets $50M Payment as GSK Extends Companies' Drug Discovery Alliance
The companies are using 23andMe's extensive genotype-phenotype database and other resources to identify targets for personalized therapeutics, continuing an alliance begun in 2018.